^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | liposomal annamycin (L-ANN) (DNA topoisomerase inhibitor, Topoisomerase II-alpha inhibitor, Topoisomerase II-beta inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases
Published date:
03/30/2021
Excerpt:
Moleculin Biotech, Inc...announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of soft tissue sarcoma (STS) lung metastases.
